Therapeutic Drug Monitoring of Everolimus in Oncology: Evidences and Perspectives

被引：22

作者：

Falkowski, Sabrina ^{[1
]}

Woillard, Jean-Baptiste ^{[2
,3
,4
]}

机构：

[1] Clin Chenieux, Dept Oncol, Limoges, France

[2] CHU Limoges, Dept Pharmacol & Toxicol, Limoges, France

[3] Univ Limoges, Limoges, France

[4] INSERM, IPPRITT, UMR1248, Limoges, France

来源：

THERAPEUTIC DRUG MONITORING | 2019年 / 41卷 / 05期

关键词：

everolimus; oncology; Therapeutic Drug Monitoring; RENAL-CELL CARCINOMA; NONFUNCTIONAL NEUROENDOCRINE TUMORS; BREAST-CANCER; POPULATION PHARMACOKINETICS; INHIBITOR EVEROLIMUS; MAMMALIAN TARGET; MTOR INHIBITORS; EFFICACY; RECEPTOR; TRIAL;

D O I：

10.1097/FTD.0000000000000628

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Everolimus is a mammalian target of rapamycin (mTOR) inhibitor that has been approved for the treatment of hormone receptor-positive advanced breast cancer, metastatic renal cancer, and neuroendocrine tumors. Although therapeutic drug monitoring (TDM) of everolimus is well established in the transplantation field, it is not currently performed in oncology. The last consensus conference about the TDM of everolimus states that for the use of everolimus in oncology, "further studies are required to determine the clinical utility of TDM for everolimus in oncology settings." In this review, the authors will discuss the current evidences and perspectives, based on observational studies available, in favor of the TDM of everolimus in oncology focusing on (1) the management of everolimus in routine practice, (2) the prerequisites for TDM of everolimus in oncology, (3) the pharmacodynamics (including a description of the biomarker of resistance and mutations in m-TOR), and (4) a general outlook.

引用

页码：568 / 574

页数：7

共 51 条

[1] Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer [J].

Aapro, M. ;

Andre, F. ;

Blackwell, K. ;

Calvo, E. ;

Jahanzeb, M. ;

Papazisis, K. ;

Porta, C. ;

Pritchard, K. ;

Ravaud, A. .

ANNALS OF ONCOLOGY, 2014, 25 (04) :763-773

[2] Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies [J].

Albiges, Laurence ;

Kube, Ulrich ;

Eymard, Jean-Christophe ;

Schmidinger, Manuela ;

Bamias, Aristotelis ;

Kelkouli, Nadia ;

Mraz, Bernhard ;

Florini, Styliani ;

Guderian, Gernot ;

Cattaneo, Agnese ;

Bergmann, Lothar .

EUROPEAN JOURNAL OF CANCER, 2015, 51 (16) :2368-2374

[3] Therapeutic drug monitoring in cancer - Are we missing a trick? [J].

Bardin, Christophe ;

Veal, Gareth ;

Paci, Angelo ;

Chatelut, Etienne ;

Astier, Alain ;

Leveque, Dominique ;

Widmer, Nicolas ;

Beijnen, Jos .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (12) :2005-2009

[4] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[5] FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo [J].

Cejka, D. ;

Kuntner, C. ;

Preusser, M. ;

Fritzer-Szekeres, M. ;

Fueger, B. J. ;

Strommer, S. ;

Werzowa, J. ;

Fuereder, T. ;

Wanek, T. ;

Zsebedics, M. ;

Mueller, M. ;

Langer, O. ;

Wacheck, V. .

BRITISH JOURNAL OF CANCER, 2009, 100 (11) :1739-1745

[6] FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer [J].

Chen, James L. ;

Appelbaum, Daniel E. ;

Kocherginsky, Masha ;

Cowey, Charles L. ;

Rathmell, Wendy Kimryn ;

McDermott, David F. ;

Stadler, Walter M. .

CANCER MEDICINE, 2013, 2 (04) :545-552

[7] Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Escudier, B. ;

Powles, T. ;

Mainwaring, P. N. ;

Rini, B. I. ;

Donskov, F. ;

Hammers, H. ;

Hutson, T. E. ;

Lee, J-L ;

Peltola, K. ;

Roth, B. J. ;

Bjarnason, G. A. ;

Geczi, L. ;

Keam, B. ;

Maroto, P. ;

Heng, D. Y. C. ;

Schmidinger, M. ;

Kantoff, P. W. ;

Borgman-Hagey, A. ;

Hessel, C. ;

Scheffold, C. ;

Schwab, G. M. ;

Tannir, N. M. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1814-1823

[8] Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications [J].

Danesi, Romano ;

Boni, Joseph P. ;

Ravaud, Alain .

CANCER TREATMENT REVIEWS, 2013, 39 (07) :784-792

[9] Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship [J].

Deppenweiler, Marine ;

Falkowski, Sabrina ;

Saint-Marcoux, Franck ;

Monchaud, Caroline ;

Picard, Nicolas ;

Laroche, Marie-Laure ;

Tubiana-Mathieu, Nicole ;

Venat-Bouvet, Laurence ;

Marquet, Pierre ;

Woillard, Jean-Baptiste .

PHARMACOLOGICAL RESEARCH, 2017, 121 :138-144

[10] Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer [J].

Dhillon, Sohita .

DRUGS, 2013, 73 (05) :475-485

← 1 2 3 4 5 6 →